^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Cutaneous Melanoma
    Drug:cisplatin (DNA synthesis inhibitor) +
    dacarbazine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Asia 2020
    Title:

    Clinicopathological characteristics and outcomes of adolescent and young adult (AYA) melanoma: Results from an Asian perspective

    Published date:
    11/17/2020
    Excerpt:
    The most common subtype was cutaneous melanoma (46%, n=34). 31 (41.9%) patients had BRAF testing. 46.4% (n=13) had BRAF V600E mutation... receiving immunotherapy. 2 (stage IV) had combination chemotherapy (Dacarbazine/Cisplatin and Paclitaxel/Bevacizumab/Caroboplatin). None received BRAF inhibitors. The median overall survival (OS) is 2.7y (range 0.1–17.7y) for all and 1y for metastatic disease. The 5y OS is 34.5%.